Loading…
Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission
To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first co...
Saved in:
Published in: | Haematologica (Roma) 2012-06, Vol.97 (6), p.915-918 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c534t-3a02139a754f2e5857e31cfce15732a5350454665fa858d9957a1c99160d8d963 |
---|---|
cites | |
container_end_page | 918 |
container_issue | 6 |
container_start_page | 915 |
container_title | Haematologica (Roma) |
container_volume | 97 |
creator | YANADA, Masamitsu KUROSAWA, Saiko TAKAMATSU, Yasushi WAKI, Fusako YOKOYAMA, Hiroki WATANABE, Masato EMI, Nobuhiko FUKUDA, Takahiro YAMAGUCHI, Takuhiro YAMASHITA, Takuya MORIUCHI, Yukiyoshi AGO, Hiroatsu TAKEUCHI, Jin NAKAMAE, Hirohisa TAGUCHI, Jun SAKURA, Toru |
description | To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first complete remission was 14% at four years, which was significantly lower than that reported in patients without monosomal karyotype, primarily due to a high relapse rate (86%). Monosomal karyotype remained significantly associated with worse overall survival among patients with unfavorable cytogenetics or complex karyotype, and even in patients who underwent allogeneic hematopoietic cell transplantation during first complete remission. These findings confirm that monosomal karyotype has a significantly adverse effect on post-remission outcome in patients with acute myeloid leukemia treated with and without allogeneic hematopoietic cell transplantation in first complete remission, emphasizing the need for the development of alternative therapies for this patient population. |
doi_str_mv | 10.3324/haematol.2011.058289 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_00d5db78d75f4be993138f6bb3fd79d1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_00d5db78d75f4be993138f6bb3fd79d1</doaj_id><sourcerecordid>1018863508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-3a02139a754f2e5857e31cfce15732a5350454665fa858d9957a1c99160d8d963</originalsourceid><addsrcrecordid>eNpVks1u1DAUhSMEoqXwBgh5g8RmBjuOE3uDhCp-KlWCBaytG-cmcevEwfZ0NC_G8-H5aUtXlu3vHp97fYriLaNrzsvq4wg4QfJuXVLG1lTIUqpnxTkTqlzJpmTPi3PKFV3VtJFnxasYbygtqVLNy-KsLJmkFWfnxd-fwQ-zjzYS3xMwm4Rk2qHztiMON7c4WSAjhNYHOw9k8pn1EzhyC2Hn025BYmeyQLI4p0hSQEjYka1NI_HhsPpNIuCcH3BGa8h4sL14iynvDDqXq2COi4M5ZR0_E-gThmxmtHi3f9X4aXGYnYVsJ8aMvC5e9OAivjmtF8Xvr19-XX5fXf_4dnX5-XplBK_SigMtGVfQiKovUUjRIGemN8hEw0sQXNBKVHUtepBCdkqJBphRitW0y9uaXxRXR93Ow41egp1y29qD1YcDHwYNIffhUFPaia5tZNeIvmpRKc647Ou25X3XqI5lrU9HrWXTTtiZPLAA7ono05vZjnrwd5rzOltUWeDDSSD4PxuMSedp7AcIM_pN1IwyKevck8xodURN8DEG7B-eYVTv46Pv46P38dHH-OSyd_9bfCi6z0sG3p8AiAZcnz_O2PjI1VQwKqtHbrTDuLUBdcyhcVm21NvtVjW61ooJ_g-2HeO5</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1018863508</pqid></control><display><type>article</type><title>Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission</title><source>PubMed Central Free</source><source>Freely Accessible Science Journals - check A-Z of ejournals</source><creator>YANADA, Masamitsu ; KUROSAWA, Saiko ; TAKAMATSU, Yasushi ; WAKI, Fusako ; YOKOYAMA, Hiroki ; WATANABE, Masato ; EMI, Nobuhiko ; FUKUDA, Takahiro ; YAMAGUCHI, Takuhiro ; YAMASHITA, Takuya ; MORIUCHI, Yukiyoshi ; AGO, Hiroatsu ; TAKEUCHI, Jin ; NAKAMAE, Hirohisa ; TAGUCHI, Jun ; SAKURA, Toru</creator><creatorcontrib>YANADA, Masamitsu ; KUROSAWA, Saiko ; TAKAMATSU, Yasushi ; WAKI, Fusako ; YOKOYAMA, Hiroki ; WATANABE, Masato ; EMI, Nobuhiko ; FUKUDA, Takahiro ; YAMAGUCHI, Takuhiro ; YAMASHITA, Takuya ; MORIUCHI, Yukiyoshi ; AGO, Hiroatsu ; TAKEUCHI, Jin ; NAKAMAE, Hirohisa ; TAGUCHI, Jun ; SAKURA, Toru</creatorcontrib><description>To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first complete remission was 14% at four years, which was significantly lower than that reported in patients without monosomal karyotype, primarily due to a high relapse rate (86%). Monosomal karyotype remained significantly associated with worse overall survival among patients with unfavorable cytogenetics or complex karyotype, and even in patients who underwent allogeneic hematopoietic cell transplantation during first complete remission. These findings confirm that monosomal karyotype has a significantly adverse effect on post-remission outcome in patients with acute myeloid leukemia treated with and without allogeneic hematopoietic cell transplantation in first complete remission, emphasizing the need for the development of alternative therapies for this patient population.</description><identifier>ISSN: 0390-6078</identifier><identifier>EISSN: 1592-8721</identifier><identifier>DOI: 10.3324/haematol.2011.058289</identifier><identifier>PMID: 22180431</identifier><language>eng</language><publisher>Pavia: Ferrata Storti Foundation</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Chromosome aberrations ; Female ; Hematologic and hematopoietic diseases ; Hematopoietic Stem Cell Transplantation ; Humans ; Karyotyping ; Leukemia, Myeloid, Acute - diagnosis ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - mortality ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical genetics ; Medical sciences ; Middle Aged ; Monosomy - diagnosis ; Monosomy - genetics ; Original and Brief Reports ; Recurrence ; Remission Induction ; Retrospective Studies ; Survival Rate ; Transplantation, Homologous ; Treatment Outcome</subject><ispartof>Haematologica (Roma), 2012-06, Vol.97 (6), p.915-918</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright© Ferrata Storti Foundation 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-3a02139a754f2e5857e31cfce15732a5350454665fa858d9957a1c99160d8d963</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366659/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366659/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26051084$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22180431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YANADA, Masamitsu</creatorcontrib><creatorcontrib>KUROSAWA, Saiko</creatorcontrib><creatorcontrib>TAKAMATSU, Yasushi</creatorcontrib><creatorcontrib>WAKI, Fusako</creatorcontrib><creatorcontrib>YOKOYAMA, Hiroki</creatorcontrib><creatorcontrib>WATANABE, Masato</creatorcontrib><creatorcontrib>EMI, Nobuhiko</creatorcontrib><creatorcontrib>FUKUDA, Takahiro</creatorcontrib><creatorcontrib>YAMAGUCHI, Takuhiro</creatorcontrib><creatorcontrib>YAMASHITA, Takuya</creatorcontrib><creatorcontrib>MORIUCHI, Yukiyoshi</creatorcontrib><creatorcontrib>AGO, Hiroatsu</creatorcontrib><creatorcontrib>TAKEUCHI, Jin</creatorcontrib><creatorcontrib>NAKAMAE, Hirohisa</creatorcontrib><creatorcontrib>TAGUCHI, Jun</creatorcontrib><creatorcontrib>SAKURA, Toru</creatorcontrib><title>Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission</title><title>Haematologica (Roma)</title><addtitle>Haematologica</addtitle><description>To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first complete remission was 14% at four years, which was significantly lower than that reported in patients without monosomal karyotype, primarily due to a high relapse rate (86%). Monosomal karyotype remained significantly associated with worse overall survival among patients with unfavorable cytogenetics or complex karyotype, and even in patients who underwent allogeneic hematopoietic cell transplantation during first complete remission. These findings confirm that monosomal karyotype has a significantly adverse effect on post-remission outcome in patients with acute myeloid leukemia treated with and without allogeneic hematopoietic cell transplantation in first complete remission, emphasizing the need for the development of alternative therapies for this patient population.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chromosome aberrations</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Karyotyping</subject><subject>Leukemia, Myeloid, Acute - diagnosis</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - mortality</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical genetics</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Monosomy - diagnosis</subject><subject>Monosomy - genetics</subject><subject>Original and Brief Reports</subject><subject>Recurrence</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><issn>0390-6078</issn><issn>1592-8721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVks1u1DAUhSMEoqXwBgh5g8RmBjuOE3uDhCp-KlWCBaytG-cmcevEwfZ0NC_G8-H5aUtXlu3vHp97fYriLaNrzsvq4wg4QfJuXVLG1lTIUqpnxTkTqlzJpmTPi3PKFV3VtJFnxasYbygtqVLNy-KsLJmkFWfnxd-fwQ-zjzYS3xMwm4Rk2qHztiMON7c4WSAjhNYHOw9k8pn1EzhyC2Hn025BYmeyQLI4p0hSQEjYka1NI_HhsPpNIuCcH3BGa8h4sL14iynvDDqXq2COi4M5ZR0_E-gThmxmtHi3f9X4aXGYnYVsJ8aMvC5e9OAivjmtF8Xvr19-XX5fXf_4dnX5-XplBK_SigMtGVfQiKovUUjRIGemN8hEw0sQXNBKVHUtepBCdkqJBphRitW0y9uaXxRXR93Ow41egp1y29qD1YcDHwYNIffhUFPaia5tZNeIvmpRKc647Ou25X3XqI5lrU9HrWXTTtiZPLAA7ono05vZjnrwd5rzOltUWeDDSSD4PxuMSedp7AcIM_pN1IwyKevck8xodURN8DEG7B-eYVTv46Pv46P38dHH-OSyd_9bfCi6z0sG3p8AiAZcnz_O2PjI1VQwKqtHbrTDuLUBdcyhcVm21NvtVjW61ooJ_g-2HeO5</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>YANADA, Masamitsu</creator><creator>KUROSAWA, Saiko</creator><creator>TAKAMATSU, Yasushi</creator><creator>WAKI, Fusako</creator><creator>YOKOYAMA, Hiroki</creator><creator>WATANABE, Masato</creator><creator>EMI, Nobuhiko</creator><creator>FUKUDA, Takahiro</creator><creator>YAMAGUCHI, Takuhiro</creator><creator>YAMASHITA, Takuya</creator><creator>MORIUCHI, Yukiyoshi</creator><creator>AGO, Hiroatsu</creator><creator>TAKEUCHI, Jin</creator><creator>NAKAMAE, Hirohisa</creator><creator>TAGUCHI, Jun</creator><creator>SAKURA, Toru</creator><general>Ferrata Storti Foundation</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20120601</creationdate><title>Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission</title><author>YANADA, Masamitsu ; KUROSAWA, Saiko ; TAKAMATSU, Yasushi ; WAKI, Fusako ; YOKOYAMA, Hiroki ; WATANABE, Masato ; EMI, Nobuhiko ; FUKUDA, Takahiro ; YAMAGUCHI, Takuhiro ; YAMASHITA, Takuya ; MORIUCHI, Yukiyoshi ; AGO, Hiroatsu ; TAKEUCHI, Jin ; NAKAMAE, Hirohisa ; TAGUCHI, Jun ; SAKURA, Toru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-3a02139a754f2e5857e31cfce15732a5350454665fa858d9957a1c99160d8d963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chromosome aberrations</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Karyotyping</topic><topic>Leukemia, Myeloid, Acute - diagnosis</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - mortality</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical genetics</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Monosomy - diagnosis</topic><topic>Monosomy - genetics</topic><topic>Original and Brief Reports</topic><topic>Recurrence</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YANADA, Masamitsu</creatorcontrib><creatorcontrib>KUROSAWA, Saiko</creatorcontrib><creatorcontrib>TAKAMATSU, Yasushi</creatorcontrib><creatorcontrib>WAKI, Fusako</creatorcontrib><creatorcontrib>YOKOYAMA, Hiroki</creatorcontrib><creatorcontrib>WATANABE, Masato</creatorcontrib><creatorcontrib>EMI, Nobuhiko</creatorcontrib><creatorcontrib>FUKUDA, Takahiro</creatorcontrib><creatorcontrib>YAMAGUCHI, Takuhiro</creatorcontrib><creatorcontrib>YAMASHITA, Takuya</creatorcontrib><creatorcontrib>MORIUCHI, Yukiyoshi</creatorcontrib><creatorcontrib>AGO, Hiroatsu</creatorcontrib><creatorcontrib>TAKEUCHI, Jin</creatorcontrib><creatorcontrib>NAKAMAE, Hirohisa</creatorcontrib><creatorcontrib>TAGUCHI, Jun</creatorcontrib><creatorcontrib>SAKURA, Toru</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Haematologica (Roma)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YANADA, Masamitsu</au><au>KUROSAWA, Saiko</au><au>TAKAMATSU, Yasushi</au><au>WAKI, Fusako</au><au>YOKOYAMA, Hiroki</au><au>WATANABE, Masato</au><au>EMI, Nobuhiko</au><au>FUKUDA, Takahiro</au><au>YAMAGUCHI, Takuhiro</au><au>YAMASHITA, Takuya</au><au>MORIUCHI, Yukiyoshi</au><au>AGO, Hiroatsu</au><au>TAKEUCHI, Jin</au><au>NAKAMAE, Hirohisa</au><au>TAGUCHI, Jun</au><au>SAKURA, Toru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission</atitle><jtitle>Haematologica (Roma)</jtitle><addtitle>Haematologica</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>97</volume><issue>6</issue><spage>915</spage><epage>918</epage><pages>915-918</pages><issn>0390-6078</issn><eissn>1592-8721</eissn><abstract>To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first complete remission was 14% at four years, which was significantly lower than that reported in patients without monosomal karyotype, primarily due to a high relapse rate (86%). Monosomal karyotype remained significantly associated with worse overall survival among patients with unfavorable cytogenetics or complex karyotype, and even in patients who underwent allogeneic hematopoietic cell transplantation during first complete remission. These findings confirm that monosomal karyotype has a significantly adverse effect on post-remission outcome in patients with acute myeloid leukemia treated with and without allogeneic hematopoietic cell transplantation in first complete remission, emphasizing the need for the development of alternative therapies for this patient population.</abstract><cop>Pavia</cop><pub>Ferrata Storti Foundation</pub><pmid>22180431</pmid><doi>10.3324/haematol.2011.058289</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0390-6078 |
ispartof | Haematologica (Roma), 2012-06, Vol.97 (6), p.915-918 |
issn | 0390-6078 1592-8721 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_00d5db78d75f4be993138f6bb3fd79d1 |
source | PubMed Central Free; Freely Accessible Science Journals - check A-Z of ejournals |
subjects | Adolescent Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Biological and medical sciences Chromosome aberrations Female Hematologic and hematopoietic diseases Hematopoietic Stem Cell Transplantation Humans Karyotyping Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical genetics Medical sciences Middle Aged Monosomy - diagnosis Monosomy - genetics Original and Brief Reports Recurrence Remission Induction Retrospective Studies Survival Rate Transplantation, Homologous Treatment Outcome |
title | Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A29%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20of%20acute%20myeloid%20leukemia%20harboring%20monosomal%20karyotype%20in%20patients%20treated%20with%20or%20without%20allogeneic%20hematopoietic%20cell%20transplantation%20after%20achieving%20complete%20remission&rft.jtitle=Haematologica%20(Roma)&rft.au=YANADA,%20Masamitsu&rft.date=2012-06-01&rft.volume=97&rft.issue=6&rft.spage=915&rft.epage=918&rft.pages=915-918&rft.issn=0390-6078&rft.eissn=1592-8721&rft_id=info:doi/10.3324/haematol.2011.058289&rft_dat=%3Cproquest_doaj_%3E1018863508%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c534t-3a02139a754f2e5857e31cfce15732a5350454665fa858d9957a1c99160d8d963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1018863508&rft_id=info:pmid/22180431&rfr_iscdi=true |